As lights around the world glow red today, Fred Hutch-based researchers lead global effort to end the pandemic
Dec. 1, 2017
| By Mary Engel / Fred Hutch News Service
The HIV Vaccine Trials Network is having a banner year. Last month in South Africa, the network launched a clinical trial called the Imbokodo Study to test an experimental vaccine regimen designed to protect against HIV subtypes around the world. Over the coming months, the Imbokodo study will roll out in four other southern African countries.
We now know that microbial communities, especially in our guts, profoundly affect immune response
Nov. 22, 2017
| By Sabin Russell / Fred Hutch News Service
Scientists at Fred Hutch are studying how the microbiome alters the immune system’s response to vaccines. Their work is already providing new insights on interactions between microbes in the body and the immune system that have implications for improving many types of vaccines.
A common, normally dormant virus called cytomegalovirus can make matters worse for patients with critical illness — and a new study by Fred Hutch's Dr. Michael Boeckh and colleagues at the University of Washington hints that preventing the virus from reawakening in these critical moments could stem some of its harm.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.